Morepen Medipath, a subsidiary of Morepen Laboratories (NSE:MOREPENLAB, BOM:500288), has received board approval to incorporate a wholly-owned subsidiary in Dubai, according to a Monday filing to the Indian stock exchanges.
The new subsidiary aims to expand the company's business-to-consumer (B2C) and business-to-business (B2B) customer segments and provide greater access to the medical device business.